Condensed Consolidated Statements of Cash Flows - USD ($) $ in Millions	3 Months Ended	6 Months Ended	9 Months Ended
	Sep. 30, 2022	Jun. 16, 2022	Sep. 24, 2021
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	$ (3.7)	$ (3.9)	$ (0.9)
Payments of claims	0.0	(629.0)	0.0
Depreciation and amortization	196.9	321.8	506.1
Share-based compensation	0.5	1.7	8.4
Deferred income taxes	(10.8)	(473.0)	(19.1)
Non-cash impairment charges	0.0	0.0	64.5
Reorganization Items, non-cash	0.0	425.4	22.5
Accretion Expense	72.3	0.0	0.0
Other Noncash Income (Expense)	(5.7)	(35.3)	6.0
Increase (Decrease) in Accounts Receivable	(9.2)	(49.8)	(105.7)
Increase (Decrease) in Inventories	(150.9)	33.2	30.9
Accounts payable	(11.6)	(3.6)	14.7
Income taxes	(27.8)	(26.9)	92.5
Acthar Gel-Related Settlement	0.0	0.0	(4.8)
Increase (Decrease) in Other Operating Assets and Liabilities, Net	17.4	(2.5)	(40.4)
Net Cash Provided by (Used in) Operating Activities	19.3	(642.3)	406.4
Payments to Acquire Property, Plant, and Equipment	15.6	33.4	39.2
Proceeds from divestitures, net of cash	(65.0)	0.0	(15.7)
Payments for (Proceeds from) Other Investing Activities	(0.2)	(0.4)	(1.4)
Net Cash Provided by (Used in) Investing Activities	49.6	(33.0)	(22.1)
Issuance of external debt	0.0		0.0
Repayment of Long-term Debt, Long-term Lease Obligation, and Capital Security	17.3	904.6	128.2
Debt financing costs	0.0	(24.1)	0.0
Net Cash Provided by (Used in) Financing Activities	(17.3)	(278.7)	(128.2)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	47.9	(957.9)	255.2
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	495.2	447.3	1,382.2
Cash and cash equivalents	391.2	297.9	1,322.6
Restricted Cash and Investments, Current	67.5	113.0	23.3
Restricted Cash and Investments, Noncurrent	36.5	36.4	36.3
Losses on divestiture	0.0	0.0	0.8
Opioid-Related Litigation Settlement liability	0.0	0.0	125.0
Adjustments to reconcile net cash from operating activities:
Depreciation and amortization	196.9	321.8	506.1
Share-based compensation	0.5	1.7	8.4
Deferred income taxes	(10.8)	(473.0)	(19.1)
Non-cash impairment charges	0.0	0.0	64.5
Reorganization Items, non-cash	0.0	425.4	22.5
Other non-cash items	5.7	35.3	(6.0)
Changes in assets and liabilities:
Accounts receivable, net	9.2	49.8	105.7
Inventories	150.9	(33.2)	(30.9)
Accounts payable	(11.6)	(3.6)	14.7
Income taxes	(27.8)	(26.9)	92.5
Other	(17.4)	2.5	40.4
Net Cash From Operating Activities	19.3	(642.3)	406.4
Cash Flows From Investing Activities:
Capital expenditures	(15.6)	(33.4)	(39.2)
Proceeds from divestitures, net of cash	65.0	0.0	15.7
Other	0.2	0.4	1.4
Net Cash From Investing Activities	49.6	(33.0)	(22.1)
Cash Flows From Financing Activities:
Repayment of external debt	(17.3)	(904.6)	(128.2)
Net Cash Provided From Financing Activities	(17.3)	(278.7)	(128.2)
Net change in cash, cash equivalents and restricted cash	47.9	(957.9)	255.2
Cash, cash equivalents and restricted cash at beginning of period	447.3	1,405.2	1,127.0
Cash, cash equivalents and restricted cash at end of period	495.2	447.3	1,382.2
Cash and cash equivalents, end of period	391.2	297.9	1,322.6
Restricted Cash and Investments, Current	67.5	113.0	23.3
Restricted Cash and Investments, Noncurrent	36.5	36.4	36.3
Retained Earnings (Deficit)
Net loss	(348.6)	(313.1)	(513.4)
Cash Flows From Operating Activities:
Net loss	$ (348.6)	$ (313.1)	$ (513.4)